Long-term cyclosporine A treatment promotes anxiety-like behavior: Possible relation with glutamate signaling in rat hippocampus

Background: Chronic immunosuppressive treatment with cyclosporine A (CsA) leads to multiple side effects, including some that occur in the central nervous system (CNS). This study aims to investigate the impact of long-term CsA treatment on anxiety behavior and verify the alterations related to glut...

Full description

Bibliographic Details
Main Authors: Marina Minto Cararo-Lopes, Débora Guerini Souza, Marcelo Ganzella, Gisele Hansel, Vanessa Kazlauckas, Paloma Segura De Mello, Larissa De Sá Lima, Elisa Mitiko Kawamoto, Luis Valmor Portela, Diogo Onofre Souza, Cristoforo Scavone, Ana Elisa Böhmer
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Journal of Affective Disorders Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666915322000865
Description
Summary:Background: Chronic immunosuppressive treatment with cyclosporine A (CsA) leads to multiple side effects, including some that occur in the central nervous system (CNS). This study aims to investigate the impact of long-term CsA treatment on anxiety behavior and verify the alterations related to glutamate signaling in the rat hippocampus. Methods: Adult male Wistar rats were intraperitoneally injected with 15 mg/kg/day CsA for eight weeks, subjected to anxiety tests, and had their brains collected for biochemistry and Western blot analysis. Results: Herein, we reported that eight weeks of CsA treatment promoted an anxiety-like effect and increased N-methyl-D-aspartate receptor (NMDAR) GluN2 subunit levels, nitric oxide synthase, and cAMP-response element binding protein (CREB) activities. Limitations: Future work should consider the impact of long-term CsA treatment on NMDAR function, as well as on other neurotransmitter signaling pathways. Peripheral side effects should also be considered a factor that could lead to CsA-induced neuropsychiatric effects. Conclusions: In conclusion, this work reports modifications to CNS adaptive responses following chronic CsA treatment, which can influence anxiogenic behavior and other associated neurotoxic events. Understanding the mechanisms underlying CsA-induced neuropsychiatric side effects is an important step toward better symptom management in patients submitted to immunosuppression in the clinical setting.
ISSN:2666-9153